News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
596,492 Results
Type
Article (42905)
Company Profile (318)
Press Release (553269)
Section
Business (167912)
Career Advice (2443)
Deals (30357)
Drug Delivery (107)
Drug Development (78767)
Employer Resources (148)
FDA (14404)
Job Trends (12995)
News (296336)
Policy (28538)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (4)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (5)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (14)
2024 Biotech Beach Digital (6)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (7)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (6)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
Academia (2671)
Academic (1)
Accelerated approval (3)
Adcomms (26)
Allergies (79)
Alliances (42926)
ALS (89)
Alzheimer's disease (1412)
Antibody-drug conjugate (ADC) (126)
Approvals (14393)
Artificial intelligence (232)
Autoimmune disease (17)
Automation (14)
Bankruptcy (325)
Best Places to Work (10685)
BIOSECURE Act (15)
Biosimilars (92)
Biotechnology (258)
Bladder cancer (63)
Brain cancer (27)
Breast cancer (249)
Cancer (1988)
Cardiovascular disease (170)
Career advice (2050)
Career pathing (31)
CAR-T (147)
Cell therapy (410)
Cervical cancer (16)
Clinical research (63604)
Collaboration (758)
Compensation (328)
Complete response letters (25)
COVID-19 (2561)
CRISPR (41)
C-suite (218)
Cystic fibrosis (101)
Data (1914)
Decentralized trials (2)
Denatured (15)
Depression (46)
Diabetes (244)
Diagnostics (5802)
Digital health (14)
Diversity (4)
Diversity, equity & inclusion (40)
Drug discovery (112)
Drug pricing (101)
Drug shortages (23)
Duchenne muscular dystrophy (89)
Earnings (61474)
Editorial (35)
Employer branding (20)
Employer resources (135)
Events (89336)
Executive appointments (644)
FDA (15464)
Featured Employer (44)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (677)
Gene editing (102)
Generative AI (20)
Gene therapy (301)
GLP-1 (713)
Government (4228)
Grass and pollen (3)
Guidances (45)
Healthcare (17261)
Huntington's disease (24)
IgA nephropathy (25)
Immunology and inflammation (118)
Indications (27)
Infectious disease (2695)
Inflammatory bowel disease (141)
Inflation Reduction Act (11)
Influenza (48)
Intellectual property (84)
Interviews (523)
IPO (14246)
IRA (45)
Job creations (2756)
Job search strategy (1683)
Kidney cancer (10)
Labor market (18)
Layoffs (443)
Leadership (19)
Legal (6064)
Liver cancer (71)
Lung cancer (298)
Lymphoma (124)
Machine learning (2)
Management (52)
Manufacturing (247)
MASH (67)
Medical device (11100)
Medtech (11104)
Mergers & acquisitions (16553)
Metabolic disorders (651)
Multiple sclerosis (70)
NASH (23)
Neurodegenerative disease (91)
Neuropsychiatric disorders (31)
Neuroscience (1914)
NextGen: Class of 2025 (5970)
Non-profit (4119)
Northern California (2199)
Now hiring (34)
Obesity (348)
Opinion (231)
Ovarian cancer (72)
Pain (79)
Pancreatic cancer (76)
Parkinson's disease (137)
Partnered (19)
Patents (199)
Patient recruitment (92)
Peanut (48)
People (54041)
Pharmaceutical (56)
Pharmacy benefit managers (13)
Phase I (19966)
Phase II (28099)
Phase III (20929)
Pipeline (987)
Podcasts (67)
Policy (111)
Postmarket research (2391)
Preclinical (8408)
Press Release (60)
Prostate cancer (92)
Psychedelics (37)
Radiopharmaceuticals (255)
Rare diseases (378)
Real estate (4497)
Recruiting (60)
Regulatory (20190)
Reports (25)
Research institute (2276)
Resumes & cover letters (359)
Rett syndrome (3)
RNA editing (3)
RSV (36)
Schizophrenia (70)
Series A (119)
Series B (79)
Service/supplier (3)
Sickle cell disease (52)
Southern California (1982)
Special edition (13)
Spinal muscular atrophy (153)
Sponsored (27)
Startups (3180)
State (2)
Stomach cancer (13)
Supply chain (54)
The Weekly (50)
United States (19388)
Vaccines (632)
Venture capitalists (36)
Webinars (11)
Weight loss (242)
Women's health (27)
Worklife (16)
Date
Today (90)
Last 7 days (597)
Last 30 days (2416)
Last 365 days (32160)
2025 (7398)
2024 (33634)
2023 (37498)
2022 (48412)
2021 (52024)
2020 (50008)
2019 (42544)
2018 (32072)
2017 (29660)
2016 (28193)
2015 (32972)
2014 (25387)
2013 (20574)
2012 (21784)
2011 (22690)
2010 (20430)
Location
Africa (742)
Alabama (51)
Alaska (4)
Arizona (164)
Arkansas (12)
Asia (36268)
Australia (7207)
California (5105)
Canada (1782)
China (450)
Colorado (228)
Connecticut (223)
Delaware (122)
Europe (81317)
Florida (747)
Georgia (170)
Idaho (55)
Illinois (448)
India (21)
Indiana (258)
Iowa (6)
Japan (139)
Kansas (91)
Kentucky (21)
Louisiana (8)
Maine (50)
Maryland (790)
Massachusetts (3811)
Michigan (194)
Minnesota (322)
Mississippi (2)
Missouri (72)
Montana (24)
Nebraska (22)
Nevada (49)
New Hampshire (65)
New Jersey (1474)
New Mexico (25)
New York (1465)
North Carolina (867)
North Dakota (5)
Northern California (2199)
Ohio (168)
Oklahoma (10)
Oregon (32)
Pennsylvania (1125)
Puerto Rico (9)
Rhode Island (24)
South America (1014)
South Carolina (16)
South Dakota (1)
Southern California (1982)
Tennessee (81)
Texas (742)
Utah (159)
Virginia (119)
Washington D.C. (52)
Washington State (475)
West Virginia (3)
Wisconsin (43)
596,492 Results for "aquestive therapeutics formerly known as monosolrx".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Press Releases
Aquestive Therapeutics to Participate in Two Upcoming Conferences in March
February 26, 2025
·
3 min read
Press Releases
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 5, 2025
·
38 min read
Press Releases
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference
February 4, 2025
·
3 min read
Press Releases
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives
January 14, 2025
·
19 min read
Pharm Country
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Aquestive Therapeutics, Inc. announced that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host investor meetings on July 9, 2024.
June 27, 2024
·
2 min read
Press Releases
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
February 12, 2025
·
10 min read
Business
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Aquestive Therapeutics, Inc. today announced the appointment of Abigail Jenkins to the Company’s Board of Directors, effective April 1, 2024.
April 1, 2024
·
6 min read
Deals
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
Aquestive Therapeutics, Inc. today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share.
March 25, 2024
·
2 min read
Business
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
Aquestive Therapeutics, Inc. today announced it has strengthened its leadership team with three executive appointments ahead of the anticipated launch of Anaphylm™.
June 3, 2024
·
8 min read
1 of 59,650
Next
